Introduction: The establishment of a neuroendocrine registry is extremely hard in developing countries. Many patients miss follow-up after surgical procedures and many die in different hospitals with a distinct national security health system number. As in any developing country, Brazil has a large movement of people to urban areas, making the tracking of former addresses impossible for patients who were treated some years prior. Therefore, it is more feasible to evaluate a demographic distribution of neuroendocrine tumors by topography or histological subtype, but the analysis of clinical events, such as progression-free survival, disease-free survival, time to progression or overall survival, is compromised.
Aim(s): To develop an easy-to-use platform for neuroendocrine patients so that clinicians and surgeons involved in the care of these individuals may input data at diagnosis and to keep track of them in the long-term. This will be tested initially in a single university center, the principal goal being to reduce the loss of data in less than 10% instead of the current 60% loss.
Materials and methods: The computorized platform was created and structure as a database specific to neuroendocrine tumors. The software will be available for use in reviewing the structure language, allowing the cross-checking of reports and supply studies. To include this data, we use The TELEFORM vs. 4.0 software. The input data includes demographics, past medical information, symptoms at diagnosis, morphological and pathological analysis, statement, treatments, follow-up, image evaluation and tumor schedule. The form will be included on the source data showing the follow-up time indicating the next visit according to the type of tumor.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: PhD Bernardo Garicochea
To read results and conclusion, please login ...
Further abstracts you may be interested in
Introduction: The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancer. Current biomarkers in NET disease have limited clinical utility.
Conference: 15th Annual ENETS conference 2018 (2018)
Presenting Author: Professor Mark Kidd
Introduction: Cooperative Group for NET was established on 22 April 2008. It continues with the practices of the Czech Carcinoid Group since 1998. The real incidence of neuroendocrine tumors is unknown. The majority remain undiagnosed. Therefore, the Czech Registry started in October 2009 to identify NET patients and to facilitate the diagnosis and therapy in centers with NET experts.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: MD Jaroslava Barkmanova
Introduction: Gastrointestinal neuroendocrine tumors (GINETs) are a heterogeneous group of tumors with variable behaviors. We analyzed baseline characteristics and outcomes of GINETs and impact of the tumor grade on the overall survival.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Doctor Jamshed Ali
Introduction: NET awareness is low in the Middle East and Asia. This registry of GEP NET patients will capture reported outcomes from physicians in clinical practice who treat patients with GEP NET.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: Dr Donald YewHee Poon
Introduction: NET are rare neoplasms. The Belgian Group of Digestive Oncology created a web-based registry to have an overview on incidence, diagnosis and therapies performed in Belgian pts. The DNET registry was launched in 01/2012.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Dr. Ivan Borbath